Pharmaceutical News RSS Feed - Pharmaceutical News

Survey reveals use of 'fake weed' among college students

Survey reveals use of 'fake weed' among college students

A survey of more than 300 college students reveals that college students who use "fake weed" or synthetic THC are most likely to have tried the drug because they were curious. Rebecca Vidourek, a University of Cincinnati assistant professor of health promotion and assistant director of the Center for Prevention Science; Keith King, a UC professor of health promotion and director of the Center for Prevention Science; and Michelle Burbage, a graduate student and graduate assistant for UC's Health Promotion and Education Program, published their findings in the current issue of the Journal of Drug Education. [More]
Sensitive toxicity test aims to detect dangerous side effects in pharmaceutical development

Sensitive toxicity test aims to detect dangerous side effects in pharmaceutical development

Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs. [More]
ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290. [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. [More]
FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2). [More]
Two-drug combination before surgery benefits women with triple-negative breast cancer

Two-drug combination before surgery benefits women with triple-negative breast cancer

A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer. [More]

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. [More]
ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

Professor Colin Garner, Chief Executive of Antibiotic Research UK (ANTRUK), the world’s first charity to tackle the impending health disaster of antibiotic resistance, welcomed the publication of the first report by the O’Neill Commission on antibiotic resistance. [More]
Midazolam drug helps recover full consciousness in traumatic brain injury patient

Midazolam drug helps recover full consciousness in traumatic brain injury patient

A patient who had suffered a traumatic brain injury unexpectedly recovered full consciousness after the administration of midazolam, a mild depressant drug of the GABA A agonists family. [More]
Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco. [More]
FDA approves Fluzone Intradermal Quadrivalent vaccine to prevent four strains of influenza virus

FDA approves Fluzone Intradermal Quadrivalent vaccine to prevent four strains of influenza virus

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone Intradermal Quadrivalent vaccine. [More]
New study investigates use of DNA barcoding to test authenticity of popular herbal supplements

New study investigates use of DNA barcoding to test authenticity of popular herbal supplements

Dr. Damon Little, Associate Curator of Bioinformatics in the Cullman Program for Molecular Systematics at The New York Botanical Garden, has just published a new study in the journal Genome investigating the use of DNA barcoding to test the authenticity of Ginkgo biloba (G. biloba), an herbal dietary supplement sold to consumers that is supposed to boost cognitive capacity. [More]
MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

The Food and Drug Administration's approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center. [More]
Danish researchers working on new type of vaccine that targets disease causing bacterium

Danish researchers working on new type of vaccine that targets disease causing bacterium

When we acquire diarrhea on a vacation, it is often caused by a bacterial infection. Now a Danish research team is working on a new type of vaccine design targeting the disease causing bacterium - if it works it may very well revolutionize not only the prevention of this disease, but also offer protection against other pathogens with a heavy disease burden such as Mycobacterium tuberculosis and antibiotic-resistant Staphylococcus aureus (MRSA). [More]
FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active. [More]
Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan Inc. today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. [More]
Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. [More]
Scientists to explore effectiveness of tadalafil drug to tackle vascular dementia

Scientists to explore effectiveness of tadalafil drug to tackle vascular dementia

Scientists are to explore whether drugs usually used to treat erectile problems by expanding blood vessels could become the next major way to tackle the dementia epidemic. [More]
Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. [More]